These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 33765515)

  • 1. A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic.
    French R; Favaro J; Aronowitz SV
    Int J Drug Policy; 2021 Aug; 94():103199. PubMed ID: 33765515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of naloxone dispensation at public health vending machines in Clark County, Nevada.
    Allen ST; O'Rourke A; Johnson JA; Cheatom C; Zhang Y; Delise B; Watkins K; Reich K; Reich R; Lockett C
    Ann Med; 2022 Dec; 54(1):2692-2700. PubMed ID: 36168975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
    Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
    Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increases in Naloxone Administrations by Emergency Medical Services Providers During the COVID-19 Pandemic: Retrospective Time Series Study.
    Khoury D; Preiss A; Geiger P; Anwar M; Conway KP
    JMIR Public Health Surveill; 2021 May; 7(5):e29298. PubMed ID: 33999828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A medical student-led model for telephone-based opioid overdose education and naloxone distribution during the COVID-19 pandemic.
    Hughes TM; Kalicki A; Huxley-Reicher Z; Toribio W; Samuels DL; Weiss JJ; Herscher M; Wang L
    Subst Abus; 2022; 43(1):988-992. PubMed ID: 35435812
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlates of experiencing and witnessing non-fatal opioid overdoses among individuals accessing harm reduction services in Philadelphia, Pennsylvania.
    Pizzicato LN; Johnson CC; Viner KM
    Subst Abus; 2020; 41(3):301-306. PubMed ID: 31644397
    [No Abstract]   [Full Text] [Related]  

  • 8. Legacies of the war on drugs: Next of kin of persons who died of opioid overdose and harm reduction interventions in Philadelphia.
    Uzwiak BA; Hudgins A; Pizzicato LN
    Int J Drug Policy; 2021 Nov; 97():103351. PubMed ID: 34252788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic.
    Courser MW; Raffle H
    J Subst Abuse Treat; 2021 Mar; 122():108220. PubMed ID: 33309390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the accessibility of harm reduction services in the United States: Measuring the impact of an automated harm reduction dispensing machine.
    Arendt D
    J Am Pharm Assoc (2003); 2023; 63(1):309-316. PubMed ID: 36549931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid education and nasal naloxone rescue kits in the emergency department.
    Dwyer K; Walley AY; Langlois BK; Mitchell PM; Nelson KP; Cromwell J; Bernstein E
    West J Emerg Med; 2015 May; 16(3):381-4. PubMed ID: 25987910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicaid prescription limits and their implications for naloxone accessibility.
    Roberts AW; Look KA; Trull G; Carpenter DM
    Drug Alcohol Depend; 2021 Jan; 218():108355. PubMed ID: 33309522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changing landscape of naloxone availability in the United States, 2011 - 2017.
    Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
    Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
    Cremer LJ; Board A; Guy GP; Schieber L; Asher A; Parker EM
    Drug Alcohol Depend; 2022 Mar; 232():109192. PubMed ID: 35065513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Innovative Model for Naloxone Use Within an OTP Setting: A Prospective Cohort Study.
    Katzman JG; Takeda MY; Bhatt SR; Moya Balasch M; Greenberg N; Yonas H
    J Addict Med; 2018; 12(2):113-118. PubMed ID: 29227321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of overdose reversal training in knowing where to get naloxone: Implications for improving naloxone access among people who use drugs.
    Schneider KE; Dayton L; Winiker AK; Tobin KE; Latkin CA
    Subst Abus; 2021; 42(4):438-443. PubMed ID: 33617733
    [No Abstract]   [Full Text] [Related]  

  • 17. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
    Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
    J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States.
    Lambdin BH; Davis CS; Wheeler E; Tueller S; Kral AH
    Drug Alcohol Depend; 2018 Jul; 188():370-376. PubMed ID: 29776688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
    Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
    Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
    Davis CS; Carr D
    Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.